Efficacy of vitamin D supplementation on adult patients with non-alcoholic fatty liver disease: a single-center experience.
| Autor: | Gad, Ahmed Ibrahim, Elmedames, Mohamed Rezk, Abdelhai, Ayman Ramadan, Marei, Ayman Mohamed, Abdel-Ghani, Hesham Atia |
|---|---|
| Předmět: |
DRUG efficacy
CLINICAL trials FATTY liver MULTIPLE regression analysis CHOLECALCIFEROL FIBROSIS VITAMIN D DIETARY supplements TREATMENT effectiveness INTRAMUSCULAR injections BLIND experiment ODDS ratio VITAMIN D deficiency ASPARTATE aminotransferase ALANINE aminotransferase DISEASE risk factors EVALUATION DISEASE complications ADULTS |
| Zdroj: | Gastroenterology & Hepatology from Bed to Bench; Winter2021, Vol. 14 Issue 1, p44-52, 9p |
| Abstrakt: | Aim: The aim of this study was to determine the efficacy of a 6-month intramuscular vitamin D supplementation in improving the liver parameters in adult patients with non-alcoholic fatty liver disease (NAFLD). Background: The association between vitamin D level and NAFLD has not been determined. Methods: A single-blinded non-randomized controlled trial was conducted in 80 NAFLD patients assigned to receive a monthly single intramuscular dose of 200,000 IU cholecalciferol/vitamin D3 (n= 40), or placebo (n= 40) for six months. Transient elastography for the measurement of controlled attenuation parameter (CAP) and liver stiffness measurements (LSM), as well as fibrosis 4 score (FIB4) and NAFLD fibrosis score (NFS) were performed. Results: The mean serum 25(OH)D was significantly increased after six months of vitamin D treatment (16.31±10.23 Vs 39.37±11.99 ng/ml). In the vitamin D group, most vitamin D deficiency patients (70% deficiency, 10% insufficiency, and 20% sufficiency) had changed to be sufficient (7.5% deficiency, 5% insufficiency, and 87.5% sufficiency). On the other hand, the values of CAP (311.9±42.2 dB/m) and LSM (6.8±2 kPa) had significantly reduced after six months of supplementation (287.0 ±44.3dB/m and 6.1 ±1.1 kPa, respectively) with significantly higher mean CAP and LSM change from baseline in vitamin D group compared to the placebo group. Furthermore, the ALT and AST levels were significantly improved in Vitamin D group compared to the placebo group (P<0.05). Multivariate regression analysis showed that lower serum 25(OH)D level was the only significant predictor for NAFLD (OR=0.89, p=0.001) in this study. Conclusion: A monthly single intramuscular dose of 200,000 IU cholecalciferol is effective in improving the laboratory and fibroscan parameters of the liver disease in NAFLD patients, which confirm a significant relationship between vitamin D deficiency and the risk of NAFLD. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|